Asunaprevir

The challenge of new therapeutic agents and combinations is to improve virological response, shorten the length of therapy and offer...


Additional, interim phase II data have demonstrating that 12- and 24-week triple DAA treatment regimens of Daclatasvir, Asunaprevir and BMS-791325...